[1] V. Lux, K. S. Kendler, “Deconstructing major depression: A validation study of the DSM-IV symptomatic criteria”, Psychol. Med., 40 (2010), 1679–1690 | DOI

[2] R. F. Zanin, E. Braganhol, L. S. Bergamin, L. F.I. Campesato, A. Z. Filho, J. C.F. Moreira, F. B. Morrone, J. Sévigny, M. R.C. Schetinger, A. T. de Souza Wyse, A. M.O. Battastini, “Differential macrophage activation alters the expression profile of NTPDase and ecto-5'-nucleotidase”, PLoS One, 7 (2012), e31205 | DOI

[3] F. Di Virgilio, S. Ceruti, P. Bramanti, M. P. Abbracchio, “Purinergic signalling in inflammation of the central nervous system”, Trends Neurosci, 32 (2009), 79–87 | DOI

[4] M. P. Abbracchio, S. Ceruti, “P1 receptors and cytokine secretion”, Purinergic Signal, 3 (2007), 13–25 | DOI

[5] G. G. Yegutkin, T. Henttinen, S. S. Samburski, J. Spychala, S. Jalkanen, “The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells”, Biochem. J., 367 (2002), 121–128 | DOI

[6] J. Linden, “Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection”, Annu. Rev. Pharmacol. Toxicol, 41 (2001), 775–787 | DOI

[7] Y. M. Wang, Z. Y. Liu, Y. H. Ai, L. N. Zhang, Y. Zou, Q. Y. Peng, “Blocking the CD38/cADPR pathway plays a double-edged role in LPS stimulated microglia”, Neuroscience, 361 (2017), 34–42 | DOI

[8] A. Cauwels, E. Rogge, B. Vandendriessche, S. Shiva, P. Brouckaert, “Extracellular ATP drives systemic inflammation, tissue damage and mortality”, Cell Death Dis., 5 (2014) | DOI

[9] M. J.L. Bours, E. L.R. Swennen, F. Di Virgilio, B. N. Cronstein, P. C. Dagnelie, “Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation”, Pharmacol. Ther., 112 (2006), 358–404 | DOI

[10] M. Solle, J. Labasi, D. G. Perregaux, E. Stam, N. Petrushova, B. H. Koller, R. J. Griffiths, C. A. Gabel, “Altered cytokine production in mice lacking P2X(7) receptors”, J. Biol. Chem., 276 (2001), 125–132 | DOI

[11] R. Coutinho-Silva, J. L. Perfettini, P. M. Persechini, A. Dautry-Varsat, D. M. Ojcius, “Modulation of Z/P2X7 receptor activity in macrophages infected with Chlamydia psittaci”, Am. J. Physiol. - Cell Physiol., 280 (2001), 2 | DOI

[12] G. Haskó, B. N. Cronstein, “Adenosine: An endogenous regulator of innate immunity”, Trends Immunol., 25 (2004), 33–39 | DOI

[13] H. Yamaguchi, T. Maruyama, Y. Urade, S. Nagata, “Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells”, Elife, 3 (2014), e02172 | DOI

[14] L. Dissing-Olesen, J. M. LeDue, R. L. Rungta, J. K. Hefendehl, H. B. Choi, B. A. MacVicar, “Activation of neuronal NMDA receptors triggers transient ATP-mediated microglial process outgrowth”, J. Neurosci., 34 (2014), 10511–10527 | DOI

[15] S. Calovi, P. Mut-Arbona, B. Sperlágh, “Microglia and the Purinergic Signaling System”, Neuroscience, 405 (2019), 137–147 | DOI

[16] L. Janks, C. V.R. Sharma, T. M. Egan, “A central role for X7 receptors in human microglia”, J. Neuroinflammation, 15 (2018), 2 | DOI

[17] T. L. Tay, J. C. Savage, C. W. Hui, K. Bisht, M. È. Tremblay, “Microglia across the lifespan: from origin to function in brain development, plasticity and cognition”, J. Physiol., 595 (2017), 1929–1945 | DOI

[18] Y. Liu, M. Alahiri, B. Ulloa, B. Xie, S. A. Sadiq, “Adenosine A2A receptor agonist ameliorates EAE and correlates with Th1 cytokine-induced blood brain barrier dysfunction via suppression of MLCK signaling pathway”, Immun. Inflamm. Dis., 6 (2018), 72–80 | DOI

[19] T. Korn, A. Kallies, “T cell responses in the central nervous system”, Nat. Rev. Immunol., 17 (2017), 179–194 | DOI

[20] Y. Ogawa, E. Furusawa, T. Saitoh, H. Sugimoto, T. Omori, S. Shimizu, H. Kondo, M. Yamazaki, H. Sakuraba, K. Oishi, “Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of Sandhoff disease”, Neurobiol. Dis., 118 (2018), 142–154 | DOI

[21] A. Vuorimaa, E. Rissanen, L. Airas, “In Vivo PET Imaging of Adenosine Receptors in Neuroinflammatory and Neurodegenerative Disease”, Contrast Media Mol. Imaging, 2017 (2017), 2 pp. | DOI | MR

[22] L. V. Sakhno, E. Y. Shevela, M. A. Tikhonova, A. A. Ostanin, E. R. Chernykh, “The Phenotypic and Functional Features of Human M2 Macrophages Generated Under Low Serum Conditions”, Scand. J. Immunol., 83 (2016), 151–159 | DOI

[23] K. M. Tye, J. J. Mirzabekov, M. R. Warden, E. A. Ferenczi, H. C. Tsai, J. Finkelstein, S. Y. Kim, A. Adhikari, K. R. Thompson, A. S. Andalman et al, “Dopamine neurons modulate neural encoding and expression of depression-related behaviour”, Nature, 493 (2013), 537–541 | DOI

[24] M. Garcia-Garcia, J. Yordanova, V. Kolev, J. Domínguez-Borràs, C. Escera, “Tuning the brain for novelty detection under emotional threat: the role of increasing gamma phase-synchronization”, Neuroimage, 49 (2010), 1038–1044 | DOI

[25] F. A. Iannotti, V. Di Marzo, S. Petrosino, “Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders”, Prog. Lipid Res., 62 (2016), 107–128 | DOI

[26] J. Y. Xu, C. Chen, “Endocannabinoids in synaptic plasticity and neuroprotection”, Neuroscientist, 21 (2015), 152–168 | DOI

[27] B. D. Heifets, P. E. Castillo, “Endocannabinoid Signaling and Long-Term Synaptic Plasticity”, Annu. Rev. Physiol., 71 (2009), 283–306 | DOI

[28] N. J. Maragakis, J. D. Rothstein, “Glutamate transporters in neurologic disease”, Arch. Neurol., 58 (2001), 365–370 | DOI

[29] K. Szydlowska, M. Tymianski, “Calcium, ischemia, excitotoxicity”, Cell Calcium, 47 (2010), 122–129 | DOI

[30] Yu. S. Mironova, N. G. Zhukova, I. A. Zhukova, V. M. Alifirova, O. P. Izhboldina, A. V. Latypova, “Bolezn Parkinsona i glutamatergicheskaya sistema”, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 118 (2018), 138–142

[31] R. Krishnadas, J. Cavanagh, Depression: An inflammatory illness?, J. Neurol. Neurosurg. Psychiatry, 83 (2012), 495–502 | DOI

[32] R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, K. W. Kelley, “From inflammation to sickness and depression: When the immune system subjugates the brain”, Nat. Rev. Neurosci., 9 (2008), 46–56 | DOI

[33] V. N. Babenko, D. A. Smagin, A. G. Galyamina, I. L. Kovalenko, N. N. Kudryavtseva, “Altered Slc25 family gene expression as markers of mitochondrial dysfunction in brain regions under experimental mixed anxiety/depression-like disorder”, BMC Neurosci, 19 (2018), 79 | DOI

[34] B. Almolda, M. Costa, M. Montoya, B. González, B. Castellano, “CD4 microglial expression correlates with spontaneous clinical improvement in the acute Lewis rat EAE model”, J. Neuroimmunol., 209 (2009), 65–80 | DOI

[35] A. Lau, M. Tymianski, “Glutamate receptors, neurotoxicity, neurodegeneration”, Pflugers Arch., 460 (2010), 525–542 | DOI

[36] J. W. Olney, “Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate”, Science, 164 (1969), 719–721 | DOI

[37] A. T. Petkova, R. D. Leapman, Z. Guo, W. M. Yau, M. P. Mattson, R. Tycko, “Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils”, Science, 307 (2005), 262–265 | DOI

[38] P. Paoletti, C. Bellone, Q. Zhou, “NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease”, Nat. Rev. Neurosci., 14 (2013), 383–400 | DOI

[39] D. S. Bredt, R. A. Nicoll, “AMPA receptor trafficking at excitatory synapses”, Neuron, 40 (2003), 361–379 | DOI

[40] S. Halpain, J. A. Girault, P. Greengard, “Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices”, Nature, 343 (1990), 369–372 | DOI

[41] A. Nishi, J. A. Bibb, G. L. Snyder, H. Higashi, A. C. Nairn, P. Greengard, “Amplification of dopaminergic signaling by a positive feedback loop”, Proc. Natl. Acad. Sci. USA, 97 (2000), 12840–12845 | DOI

[42] A. Belkhiri, S. Zhu, W. El-Rifai, “DARPP-32: from neurotransmission to cancer”, Oncotarget, 7 (2016), 17631–17640 | DOI

[43] S. Yagishita, A. Hayashi-Takagi, G. C.R. Ellis-Davies, H. Urakubo, S. Ishii, H. Kasai, “A critical time window for dopamine actions on the structural plasticity of dendritic spines”, Science, 345 (2014), 1616–1620 | DOI

[44] A. G. Nair, U. S. Bhalla, J. Hellgren Kotaleski, “Role of DARPP-32 and ARPP-21 in the Emergence of Temporal Constraints on Striatal Calcium and Dopamine Integration”, PLoS Comput. Biol., 12 (2016), e1005080 | DOI

[45] Z. Chen, B. D. Trapp, “Microglia, neuroprotection”, J. Neurochem., 136 (2016), 10–17 | DOI

[46] T. Masuda, R. Sankowski, O. Staszewski, M. Prinz, “Microglia Heterogeneity in the Single-Cell Era”, Cell Rep., 30 (2020), 1271–1281 | DOI

[47] N. Wang, H. Liang, K. Zen, “Molecular mechanisms that influence the macrophage M1-M2 polarization balance”, Front. Immunol., 5 (2014), 614

[48] L. Zhang, J. Zhang, Z. You, “Switching of the Microglial Activation Phenotype Is a Possible Treatment for Depression Disorder”, Front. Cell. Neurosci., 12 (2018), 306 | DOI

[49] R. H. Tang, R. Q. Qi, H. Y. Liu, “Interleukin-4 affects microglial autophagic flux”, Neural Regen. Res., 14 (2019), 1594–1602 | DOI

[50] G. Navarro, D. Borroto-Escuela, E. Angelats, Í. Etayo, I. Reyes-Resina, M. Pulido-Salgado, A. I. Rodríguez-Pérez, E. I. Canela, J. Saura, J. L. Lanciego et al., “Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia”, Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia, 67 (2018), 139–151

[51] G. Navarro, P. Morales, C. Rodríguez-Cueto, J. Fernández-Ruiz, N. Jagerovic, R. Franco, “Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders”, Front. Neurosci., 10 (2016), 406 | DOI

[52] I. Reyes-Resina, G. Navarro, D. Aguinaga, E. I. Canela, C. T. Schoeder, M. Załuski, K. Kieć-Kononowicz, C. A. Saura, C. E. Müller, R. Franco, “Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases”, Biochem. Pharmacol., 157 (2018), 169–179 | DOI

[53] G. G. Muccioli, C. Xu, E. Odah, E. Cudaback, J. A. Cisneros, D. M. Lambert, M. L. López Rodríguez, S. Bajjalieh, N. Stella, “Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells”, J. Neurosci., 27 (2007), 2883–2889 | DOI

[54] J. L. Blankman, G. M. Simon, B. F. Cravatt, “A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol”, Chem. Biol., 14 (2007), 1347–1356 | DOI

[55] G. A. Cabral, E. S. Raborn, L. Griffin, J. Dennis, F. Marciano-Cabral, “CB 2 receptors in the brain: Role in central immune function”, Br. J. Pharmacol., 153 (2008), 240–251 | DOI

[56] L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, N. Stella, “Nonpsychotropic cannabinoid receptors regulate microglial cell migration”, J. Neurosci., 23 (2003), 1398–1405 | DOI

[57] L. Cristino, T. Bisogno, V. Di Marzo, “Cannabinoids and the expanded endocannabinoid system in neurological disorders”, Nat. Rev. Neurol., 16 (2020), 9–29 | DOI

[58] H. C. Lu, K. MacKie, “An introduction to the endogenous cannabinoid system”, Biol. Psychiatry, 79 (2016), 516–525 | DOI

[59] J. R. Savinainen, S. M. Saario, J. T. Laitinen, “The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors”, Acta Physiol. (Oxf)., 204 (2012), 267–276 | DOI

[60] R. Franco, I. Reyes-Resina, D. Aguinaga, A. Lillo, J. Jiménez, I. Raïch, D. O. Borroto-Escuela, C. Ferreiro-Vera, E. I. Canela, V. Sánchez de Medina et al, “Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists”, Glia, 67 (2019), 2410–2423 | DOI

[61] P. K. Chanda, Y. Gao, L. Mark, J. Btesh, B. W. Strassle, P. Lu, M. J. Piesla, M. Y. Zhang, B. Bingham, A. Uveges et al, “Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system”, Mol. Pharmacol., 78 (2010), 996–1003 | DOI

[62] J. E. Schlosburg, J. L. Blankman, J. Z. Long, D. K. Nomura, B. Pan, S. G. Kinsey, P. T. Nguyen, D. Ramesh, L. Booker, J. J. Burston et al, “Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system”, Nat. Neurosci., 13 (2010), 1113–1119 | DOI

[63] G. G. Szabó, N. Lenkey, N. Holderith, T. Andrási, Z. Nusser, N. Hájos, “Presynaptic calcium channel inhibition underlies CB$_1$ cannabinoid receptor-mediated suppression of GABA release”, J. Neurosci., 34 (2014), 7958–7963 | DOI

[64] S. Gordon, F. O. Martinez, “Alternative activation of macrophages: Mechanism and functions”, Immunity, 32 (2010), 593–604 | DOI

[65] J. Zhou, J. Chen, W. Xu, Y. Liu, Z. Song, Z. Wen, X. Jian, J. Yu, X. Ma, Z. Wang et al, “Common variants in SATB2 are associated with schizophrenia in Uygur Chinese population”, Psychiatr. Genet., 29 (2019), 120–126 | DOI

[66] K. Kawahara, M. Suenobu, A. Yoshida, K. Koga, A. Hyodo, H. Ohtsuka, A. Kuniyasu, N. Tamamaki, Y. Sugimoto, H. Nakayama, “Intracerebral microinjection of interleukin-4/interleukin-13 reduces $\beta$-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice”, Neuroscience, 207 (2012), 243–260 | DOI

[67] M.-M. Jin, F. Wang, D. Qi, W.-W. Liu, C. Gu, C. J. Mao, Y. P. Yang, Z. Zhao, L.-F. Hu, C.-F. Liu, “A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration”, Front. Aging Neurosci., 10 (2018), 378 | DOI

[68] J. Ji, T.-F. Xue, X.-D. Guo, J. Yang, R.-B. Guo, J. Wang, J.-Y. Huang, X.-J. Zhao, X.-L. Sun, “Antagonizing peroxisome proliferator-activated receptor $\gamma$ facilitates M1-to-M2 shift of microglia by enhancing autophagy via the LKB1-AMPK signaling pathway”, Aging Cell, 17 (2018), e12774 | DOI

[69] M. Ries, M. Sastre, “Mechanisms of A$\beta$ clearance and degradation by glial cells”, Front. Aging Neurosci, 8 (2016) | DOI

[70] N. Braun, J. Sévigny, S. C. Robson, K. Enjyoji, O. Guckelberger, K. Hammer, F. Di Virgilio, H. Zimmermann, “Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain”, Eur. J. Neurosci., 12 (2000), 4357–4366

[71] P. N. Kravchenko, E. K. Oleinik, “Sistema regulyatornykh T-kletok i autoimmunnye protsessy”, Trudy Karelskogo nauchnogo tsentra Rossiiskoi akademii nauk, 2013, 18–30

[72] L. A. Tashireva, V. M. Perelmuter, V. N. Manskikh, E. V. Denisov, O. E. Saveleva, E. V. Kaigorodova, M. V. Zavyalova, “Tipy immunovospalitelnykh reaktsii kak algoritmy vzaimodeistviya kletok v usloviyakh reparativnoi regeneratsii i opukholevogo rosta”, Biokhimiya, 82 (2017), 732–748

[73] L.-M. Wang, Y. Zhang, X. Li, M.-L. Zhang, L. Zhu, G.-X. Zhang, Y.-M. Xu, “Nr4a1 plays a crucial modulatory role in Th1/Th17 cell responses and CNS autoimmunity”, Brain. Behav. Immun., 68 (2018), 44–55 | DOI

[74] D. J. Araujo, K. Toriumi, C. O. Escamilla, A. Kulkarni, A. G. Anderson, M. Harper, N. Usui, J. Ellegood, J. P. Lerch, S. G. Birnbaum et al, “Foxp1 in forebrain pyramidal neurons controls gene expression required for spatial learning and synaptic plasticity”, J. Neurosci., 37 (2017), 10917–10931 | DOI

[75] L. Shen, H. S. Nam, P. Song, H. Moore, S. A. Anderson, “FoxG1 haploinsufficiency results in impaired neurogenesis in the postnatal hippocampus and contextual memory deficits”, Hippocampus, 16 (2006), 875–890 | DOI

[76] J. D. Hawk, T. Abel, “The role of NR4A transcription factors in memory formation”, Brain Res. Bull., 85 (2011), 21–29 | DOI

[77] B. Beck, G. Pourié, “Ghrelin, neuropeptide Y, and other feeding-regulatory peptides active in the Hippocampus: Role in learning and memory”, Nutr. Rev., 71 (2013), 541–561 | DOI

[78] I. H. Deakin, B. R. Godlewska, M. A. Walker, G. J. Huang, M. H. Schwab, K. A. Nave, A. J. Law, P. J. Harrison, “Altered hippocampal gene expression and structure in transgenic mice overexpressing neuregulin 1 (Nrg1) type I”, Transl. Psychiatry, 8 (2018), 229 | DOI

[79] P. B. Chen, R. Kawaguchi, C. Blum, J. M. Achiro, G. Coppola, T. J. O'Dell, K. C. Martin, “Mapping gene expression in excitatory neurons during hippocampal late-phase long-term potentiation”, Front. Mol. Neurosci., 10 (2017), 39

[80] M. S. Cembrowski, L. Wang, K. Sugino, B. C. Shields, N. Spruston, “Hipposeq: A comprehensive RNA-seq database of gene expression in hippocampal principal neurons”, eLife, 5 (2016), e14997 | DOI

[81] A. E. Umryukhin, “Neiromediatornye gippokampalnye mekhanizmy stressornogo povedeniya i reaktsii izbeganiya”, Vestnik novykh meditsinskikh tekhnologii, 2013, no. 1

[82] L. Guo, M. Niu, J. Yang, L. Li, S. Liu, Y. Sun, Z. Zhou, Y. Zhou, “GHS-R1a Deficiency Alleviates Depression-Related Behaviors After Chronic Social Defeat Stress”, Front. Neurosci., 13 (2019)

[83] E. M. Inyushkina, “Leptin anoreksigennyi regulyatornyi polipeptid s respiratornoi aktivnostyu”, Vestnik Samarskogo gosudarstvennogo universiteta. Estestvennonauchnaya seriya, 2 (2006), 168–177

[84] G. E. Mazo, G. V. Rukavishnikov, A. O. Kibitov, L. L. Kelin, A. V. Bobrovskii, “Narusheniya pischevogo povedeniya u patsientov s depressivnym rasstroistvom: patofiziologicheskie mekhanizmy komorbidnosti”, Uspekhi fiziologicheskikh nauk, 50 (2019), 31–41

[85] Y. M. Morozov, M. Koch, P. Rakic, T. L. Horvath, “Cannabinoid type 1 receptor-containing axons innervate NPY/AgRP neurons in the mouse arcuate nucleus”, Mol. Metab., 6 (2017), 374–381 | DOI

[86] R. A. Costa, I. R. Ferreira, H. A. Cintra, L. H. F. Gomes, L. da C. Guida, “Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome”, Front. Endocrinol. (Lausanne), 10 (2019)

[87] Y. Shen, M. Tian, Y. Zheng, F. Gong, A. K. Y. Fu, N. Y. Ip, “Stimulation of the Hippocampal POMC/MC4R Circuit Alleviates Synaptic Plasticity Impairment in an Alzheimer's Disease Model”, Cell Rep., 17 (2016), 1819–1831 | DOI

[88] I. V. Gmoshinskii, S. A. Apryatin, V. A. Shipelin, D. B. Nikityuk, “Neiromediatory i neiropeptidy biomarkery metabolicheskikh narushenii pri ozhirenii”, Problemy endokrinologii, 64 (2018), 258–269

[89] G. P. Mavani, M. V. DeVita, M. F. Michelis, “A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin”, Front. Med., 2 (2015), 19

[90] E. A. Bordt, C. J. Smith, T. G. Demarest, S. D. Bilbo, M. A. Kingsbury, “Mitochondria, Oxytocin, and Vasopressin: Unfolding the Inflammatory Protein Response”, Neurotox. Res., 36 (2019), 239–256 | DOI